194 related articles for article (PubMed ID: 4809201)
1. Effect of clofibrate on plasma glucose and serum immunoreactive insulin in patients with hyperlipoproteinemia.
Fenderson RW; Sekowski I; Mohan C; Deutsch S; Benjamin F; Samuel P
Am J Clin Nutr; 1974 Jan; 27(1):22-8. PubMed ID: 4809201
[No Abstract] [Full Text] [Related]
2. Influence of obesity on the relationship between insulin and triglyceride levels in endogenous hypertriglyceridemia.
Bagdade JD; Bierman EL; Porte D
Diabetes; 1971 Oct; 20(10):664-72. PubMed ID: 5110698
[No Abstract] [Full Text] [Related]
3. [Effect of clofibrate on glucose tolerance and insulin secretion in patients with endogenous hypertriglyceridemia (author's transl)].
Schwandt P; Weisweiler P; Neureuther G; Wilkening J
MMW Munch Med Wochenschr; 1976 Mar; 118(12):351-4. PubMed ID: 177863
[TBL] [Abstract][Full Text] [Related]
4. Studies of hyperlipidemia in the HGH-deficient state.
Merimee TJ; Hollander W; Fineberg SE
Metabolism; 1972 Nov; 21(11):1053-61. PubMed ID: 4342932
[No Abstract] [Full Text] [Related]
5. Diurnal patterns of blood sugar, plasma insulin, free fatty acid and triglyceride levels in normal subjects and in patients with type IV hyperlipoproteinemia and the effect of meal frequency.
Schlierf G; Raetzer H
Nutr Metab; 1972; 14(2):113-26. PubMed ID: 5051903
[No Abstract] [Full Text] [Related]
6. Human plasma fatty acid composition: the features of hyperlipoproteinemia and the influence of -linolenate and clofibrate.
Takayasu K; Tada T; Okada F; Yoshikawa I
Jpn Circ J; 1971 Sep; 35(9):1059-69. PubMed ID: 5172104
[No Abstract] [Full Text] [Related]
7. The relationship between insulin secretion and triglyceride concentration in endogenous lipemia.
Eaton BP; Nye WH
J Lab Clin Med; 1973 May; 81(5):682-95. PubMed ID: 4349136
[No Abstract] [Full Text] [Related]
8. Type IV hyperlipoproteinemia. A critical appraisal.
Schonfeld G; Kudzma DJ
Arch Intern Med; 1973 Jul; 132(1):55-62. PubMed ID: 4716427
[No Abstract] [Full Text] [Related]
9. Effects of clofibrate treatment on arginine-induced insulin secretion in endogenous hypertriglyceridemia.
Fedele D; Tiengo A; Muggeo M; Nosadini R; Crepaldi G
Atherosclerosis; 1976; 25(2-3):191-8. PubMed ID: 1008908
[TBL] [Abstract][Full Text] [Related]
10. Effect of clofibrate on arginine-stimulated glucagon and insulin secretion in man.
Eaton RP; Schade DS
Metabolism; 1974 May; 23(5):445-54. PubMed ID: 4825301
[No Abstract] [Full Text] [Related]
11. Effects of clofibrate on glucose tolerance, serum insulin, serum lipoproteins and plasma fibrinogen.
Lithell H; Boberg J; Hedstrand H; Hellsing K; Ljunghall S; Vessby B
Eur J Clin Pharmacol; 1977 Aug; 12(1):51-7. PubMed ID: 332503
[No Abstract] [Full Text] [Related]
12. Glucagon secretion in primary endogenous hypertriglyceridemia before and after clofibrate treatment.
Tiengo A; Muggeo M; Assan R; Fedele D; Crepaldi G
Metabolism; 1975 Aug; 24(8):901-14. PubMed ID: 1143089
[TBL] [Abstract][Full Text] [Related]
13. Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.
Ferrari C; Frezzati S; Romussi M; Bertazzoni A; Testori GP; Antonini S; Paracchi A
Metabolism; 1977 Feb; 26(2):129-39. PubMed ID: 834147
[TBL] [Abstract][Full Text] [Related]
14. Ultracentrifugal demonstration of floating beta lipoproteins in type 3 hyperlipoproteinemia. Diagnostic value.
Aubry F; Lapierre YL; Noël C; Davignon J
Ann Intern Med; 1971 Aug; 75(2):231-7. PubMed ID: 5558651
[No Abstract] [Full Text] [Related]
15. Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia.
Feldman EB; Gluck FB; Carter AC
J Clin Pharmacol; 1978; 18(5-6):241-8. PubMed ID: 346616
[TBL] [Abstract][Full Text] [Related]
16. Diurnal patterns of plasma triglycerides and free fatty acids in normal subjects and in patients with endogenous (type IV) hyperlipoproteinemia.
Schlierf G; Reinheimer W; Stossberg V
Nutr Metab; 1971; 13(2):80-91. PubMed ID: 5123770
[No Abstract] [Full Text] [Related]
17. Study of serum insulin in atherosclerotic patients with endogenous hypertriglyceridemia (type 3 and IV hyperlipoproteinemia).
Kuo PT; Feng LY
Metabolism; 1970 May; 19(5):372-80. PubMed ID: 5442617
[No Abstract] [Full Text] [Related]
18. Effects of clofibrate therapy on glucose tolerance, insulin secretion and serum lipids in subjects with hyperlipoproteinemia and impaired glucose tolerance. A follow-up study over a five-year period.
Ratzmann ML; Rjasanowski I; Bruns W; Ratzmann KP
Exp Clin Endocrinol; 1983 Aug; 82(2):216-21. PubMed ID: 6354731
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone secretion in primary endogenous hypertriglyceridemia.
Muggeo M; Fedele D; Tiengo A; Crepaldi G
Horm Metab Res; 1973 May; 5(3):224-5. PubMed ID: 4714551
[No Abstract] [Full Text] [Related]
20. Immunoreactive insulin, glucose tolerance, and carbohydrate inducibility in types II, 3, IV, and V hyperlipoproteinemia.
Glueck CJ; Levy RI; Fredrickson DS
Diabetes; 1969 Nov; 18(11):739-47. PubMed ID: 5348517
[No Abstract] [Full Text] [Related]
[Next] [New Search]
